Search results
Results from the WOW.Com Content Network
CD11c, also known as Integrin, alpha X (complement component 3 receptor 4 subunit) (ITGAX), is a gene that encodes for CD11c . [ 5 ] [ 6 ] CD11c is an integrin alpha X chain protein.
A knockout mouse (left) that is a model for obesity, compared with a normal mouse. There are several thousand different strains of knockout mice. [3] Many mouse models are named after the gene that has been inactivated.
[2] [3] Many of the targeted alleles are designed so that they can generate both complete and conditional gene knockout mice. [3] [4] The IKMC was initiated on March 15, 2007, at a meeting in Brussels. By 2011, Nature reported that approximately 17,000 different genes have already been disabled by the consortium, "leaving only around 3,000 more ...
Gene knock-in originated as a slight modification of the original knockout technique developed by Martin Evans, Oliver Smithies, and Mario Capecchi.Traditionally, knock-in techniques have relied on homologous recombination to drive targeted gene replacement, although other methods using a transposon-mediated system to insert the target gene have been developed. [3]
The International Mouse Phenotyping Consortium (IMPC) is an international scientific endeavour to create and characterize the phenotype of 20,000 knockout mouse strains. [1] [2] [3] Launched in September 2011, [1] the consortium consists of over 15 research institutes across four continents with funding provided by the NIH, European national governments and the partner institutions.
Credits: $59.00 for 100 credits, $160.00 for 500 credit, or $289.00 for 1000 credits Pros. Great for married individuals. Free for female users “Traveling Man” feature when out of town. Cons ...
The genetically modified mouse in which a gene affecting hair growth has been knocked out (left) shown next to a normal lab mouse. A genetically modified mouse, genetically engineered mouse model (GEMM) [1] or transgenic mouse is a mouse (Mus musculus) that has had its genome altered through the use of genetic engineering techniques.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. [2]